ArticleThe Journal of experimental medicine2011
Genomic loss of the putative tumor suppressor gene E2A in human lymphoma.
Article in The Journal of experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Complex Genomic Alterations in TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia Involving EPOR/JAK2 Amplification, ERG Copy Gains, and TCF3 Deletion.Genes, chromosomes & cancer · 2026Article
- Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia.Blood advances · 2023Article
- Differential usage of transcriptional repressor Zeb2 enhancers distinguishes adult and embryonic hematopoiesis.Immunity · 2021Article
- RecurrentBlood · 2019Article
- Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells.Frontiers of medicine · 2018Review
- Genome-Wide Analysis of Interchromosomal Interaction Probabilities Reveals Chained Translocations and Overrepresentation of Translocation Breakpoints in Genes in a Cutaneous T-Cell Lymphoma Cell Line.Frontiers in oncology · 2018Article
- NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.Oncotarget · 2017Article
- Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.Oncotarget · 2017Article
- G-quadruplex DNA structures can interfere with uracil glycosylase activity in vitro.Mutagenesis · 2016Article
- Repression of TCF3/E2A contributes to Hodgkin lymphomagenesis.Oncotarget · 2016Article
- Mature T-cell leukemias: Molecular and Clinical Aspects.Current hematologic malignancy reports · 2015Review
- Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.Nature communications · 2015Article
- Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.The Journal of investigative dermatology · 2015Article
- Sites of instability in the human TCF3 (E2A) gene adopt G-quadruplex DNA structures in vitro.Frontiers in genetics · 2015Article
- SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.PLoS genetics · 2014Article
- NKp46-specific expression on skin-resident CD4(+) lymphocytes in mycosis fungoides and Sézary syndrome.The Journal of investigative dermatology · 2014Article
- E proteins in lymphocyte development and lymphoid diseases.Current topics in developmental biology · 2014Review
- E2A predicts prognosis of colorectal cancer patients and regulates cancer cell growth by targeting miR-320a.PloS one · 2014Article
- Cell-intrinsic in vivo requirement for the E47-p21 pathway in long-term hematopoietic stem cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells.The Journal of clinical investigation · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sézary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepression of the protooncogene MYC and the cell cycle regulator CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic signaling pathways, including the Ras pathway. Several of these genes are down-regulated or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of E2A in human lymphoid cells and could help to develop new treatment strategies for human lymphomas with altered E2A activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.